Cargando…
A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
OBJECTIVE: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer’s disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. METHOD: “Visinin-like protein-1” and “alzheimer’s disease” were employed...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Riyadh : Armed Forces Hospital
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726829/ https://www.ncbi.nlm.nih.gov/pubmed/28416790 http://dx.doi.org/10.17712/nsj.2017.2.20160557 |
_version_ | 1783285765070913536 |
---|---|
author | Hu, Xiaohui Yang, Yan Gong, Daokai |
author_facet | Hu, Xiaohui Yang, Yan Gong, Daokai |
author_sort | Hu, Xiaohui |
collection | PubMed |
description | OBJECTIVE: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer’s disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. METHOD: “Visinin-like protein-1” and “alzheimer’s disease” were employed to search “PubMed”, “Springer” and “Medline” databases until July 2016 and standard mean difference (Std.MD) was calculated. Besides, subgroup analysis and meta-regression were performed to explore the possible heterogeneity sources. RESULTS: Seven studies involved 1151 participants were pooled. The CSF VLP-1 in AD patients was higher than that in healthy controls and MCI patients (pooled Std.MD=0.81, 95% CI: [0.47, 1.16], p<0.00001). As shown by subgroup analysis, population variations were one of heterogeneity sources. Meta-regression revealed that Hedges’s g of CSF VLP-1 was correlated with Std.MD of t-tau (r=0.560, p=0.006) and Ab42 (r=-0.386, p=0.013). CONCLUSION: The CSF VLP-1 in AD patients is higher than that in healthy controls and MCI patients. The changes of VLP-1 in AD patients relative to healthy controls and MCI patients is less pronounced than that of core biomarkers, such as Ab42, t-tau and p-tau. Population variations, increasing t-tau and decreasing Ab42 in AD patients relative to healthy controls and MCI patients were the main sources of heterogeneity. |
format | Online Article Text |
id | pubmed-5726829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Riyadh : Armed Forces Hospital |
record_format | MEDLINE/PubMed |
spelling | pubmed-57268292017-12-18 A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients Hu, Xiaohui Yang, Yan Gong, Daokai Neurosciences (Riyadh) Systematic Review OBJECTIVE: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer’s disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. METHOD: “Visinin-like protein-1” and “alzheimer’s disease” were employed to search “PubMed”, “Springer” and “Medline” databases until July 2016 and standard mean difference (Std.MD) was calculated. Besides, subgroup analysis and meta-regression were performed to explore the possible heterogeneity sources. RESULTS: Seven studies involved 1151 participants were pooled. The CSF VLP-1 in AD patients was higher than that in healthy controls and MCI patients (pooled Std.MD=0.81, 95% CI: [0.47, 1.16], p<0.00001). As shown by subgroup analysis, population variations were one of heterogeneity sources. Meta-regression revealed that Hedges’s g of CSF VLP-1 was correlated with Std.MD of t-tau (r=0.560, p=0.006) and Ab42 (r=-0.386, p=0.013). CONCLUSION: The CSF VLP-1 in AD patients is higher than that in healthy controls and MCI patients. The changes of VLP-1 in AD patients relative to healthy controls and MCI patients is less pronounced than that of core biomarkers, such as Ab42, t-tau and p-tau. Population variations, increasing t-tau and decreasing Ab42 in AD patients relative to healthy controls and MCI patients were the main sources of heterogeneity. Riyadh : Armed Forces Hospital 2017-04 /pmc/articles/PMC5726829/ /pubmed/28416790 http://dx.doi.org/10.17712/nsj.2017.2.20160557 Text en Copyright: © Neurosciences http://creativecommons.org/licenses/by/3.0/ Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. |
spellingShingle | Systematic Review Hu, Xiaohui Yang, Yan Gong, Daokai A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients |
title | A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients |
title_full | A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients |
title_fullStr | A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients |
title_full_unstemmed | A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients |
title_short | A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients |
title_sort | meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726829/ https://www.ncbi.nlm.nih.gov/pubmed/28416790 http://dx.doi.org/10.17712/nsj.2017.2.20160557 |
work_keys_str_mv | AT huxiaohui ametaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients AT yangyan ametaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients AT gongdaokai ametaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients AT huxiaohui metaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients AT yangyan metaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients AT gongdaokai metaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients |